Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosis

   The Food and Drug Administration (FDA) granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.), a subcutaneous formulation of daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.

ASH 2020 AL amyloidosis highlights

      Myeloma Patients Europe interviewed Dr Giampaolo Merlini, the Research Director and AL amyloidosis expert from Policlinico San Matteo, University of Pavia, in Italy, to summarise the main highlights on this disease presented at the American Society of Hematology (ASH) Annual Meeting. Click to hear a summary of the most important studies presented at ASH 2020 and his views on the future of AL amyloidosis treatment.  

ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patients

    A new study suggests the monoclonal antibody daratumumab has similar benefits when delivered via subcutaneous injection as it does when delivered intravenously to patients which myeloma persists or recurs after first-line treatments. Patients given subcutaneous daratumumab along with the immunomodulator pomalidomide and the anti-inflammatory steroid dexamethasone were 37% less likely to die or have their disease worsen compared to patients who received pomalidomide and dexamethasone alone in the phase III trial.